The biotech has quickly turned a cell therapy approval into one of the more lucrative recent sales for a priority review ...

Reports of severe adverse events in some people who received the chikungunya vaccine have spurred regulators in Europe and ...

The proposal would see the HHS set price targets other countries pay for certain medicines, kicking off a round of ...

Improvements in our understanding of the human genome, technological tools like artificial intelligence, and global ...

Some providers may need to reduce services, lay off staff or close their doors if Congress enacts major cuts to the ...

A version of meloxicam designed to work faster has beat out a placebo in two late-stage studies focused on post-surgical ...

The company added to a recent flurry of pledges by pharmaceutical companies, promising $11 billion in new capital and ...

Vor Bio, Korro Bio, Insitro and Rallybio revealed plans to lay off chunks of their respective workforces in the latest job ...

The startup’s first prospect is a heart medicine that works differently than the hypertrophic cardiomyopathy drugs developed ...

Siren Biotechnology is trying to raise $5 million via the type of crowdfunding round that’s rarely used by young drugmakers.

Sales of the company’s copycat to J&J’s blockbuster reached $150 million in the first quarter, adding to a surge in revenue ...

Already facing headwinds caused by a patient’s death and treatment delays, the biotech now may have to contend with a less ...